| |
| |
|
| Insider
Information: |
Duvall Diantha |
| Relationship: |
CHIEF FINANCIAL OFFICER |
| City: |
Waltham |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
75,388 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$44,803 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
75,388 |
|
|
| Total
Value |
$44,803 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Bioverativ Inc. |
BIVV |
Chief Accounting Officer |
2018-03-08 |
0 |
2017-05-02 |
0 |
Premium* |
|
|
Genocea Biosciences, Inc. |
GNCA |
CHIEF FINANCIAL OFFICER |
2022-06-02 |
75,388 |
2020-04-02 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
15 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| GNCA |
Genocea Biosciences, Inc. |
CHIEF FINANCIAL OFFICER |
• – – |
2022-06-02 |
4 |
S |
$0.06 |
$81 |
D/D |
(1,355) |
75,388 |
0 |
- |
|
| GNCA |
Genocea Biosciences, Inc. |
CHIEF FINANCIAL OFFICER |
• – – |
2022-05-26 |
4 |
S |
$0.08 |
$1,867 |
D/D |
(24,407) |
76,743 |
0 |
- |
|
| GNCA |
Genocea Biosciences, Inc. |
CHIEF FINANCIAL OFFICER |
• – – |
2022-04-04 |
4 |
S |
$1.25 |
$1,204 |
D/D |
(963) |
91,775 |
0 |
- |
|
| GNCA |
Genocea Biosciences, Inc. |
CHIEF FINANCIAL OFFICER |
• – – |
2022-03-16 |
4 |
S |
$1.10 |
$3,160 |
D/D |
(2,873) |
92,738 |
0 |
- |
|
| GNCA |
Genocea Biosciences, Inc. |
CHIEF FINANCIAL OFFICER |
• – – |
2022-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
37,500 |
95,611 |
0 |
- |
|
| GNCA |
Genocea Biosciences, Inc. |
CHIEF FINANCIAL OFFICER |
• – – |
2021-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
37,500 |
37,500 |
0 |
- |
|
| GNCA |
Genocea Biosciences, Inc. |
CHIEF FINANCIAL OFFICER |
• – – |
2020-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,623 |
6,623 |
0 |
- |
|
| GNCA |
Genocea Biosciences, Inc. |
CHIEF FINANCIAL OFFICER |
• – – |
2020-04-02 |
4 |
A |
$0.00 |
$0 |
D/D |
12,299 |
12,299 |
0 |
- |
|
| BIVV |
Bioverativ Inc. |
Chief Accounting Officer |
• • – |
2018-03-08 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,791) |
0 |
0 |
- |
|
| BIVV |
Bioverativ Inc. |
Chief Accounting Officer |
• • – |
2018-03-02 |
4 |
D |
$104.73 |
$10,997 |
D/D |
(105) |
2,791 |
0 |
- |
|
| BIVV |
Bioverativ Inc. |
Chief Accounting Officer |
• • – |
2018-02-22 |
4 |
D |
$104.30 |
$17,522 |
D/D |
(168) |
2,896 |
0 |
- |
|
| BIVV |
Bioverativ Inc. |
Chief Accounting Officer |
• • – |
2018-02-14 |
4 |
D |
$103.52 |
$46,998 |
D/D |
(454) |
3,064 |
0 |
- |
|
| BIVV |
Bioverativ Inc. |
Chief Accounting Officer |
• • – |
2018-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,390 |
3,518 |
0 |
- |
|
| BIVV |
Bioverativ Inc. |
Chief Accounting Officer |
• • – |
2017-06-28 |
4 |
AS |
$60.47 |
$49,464 |
D/D |
(818) |
2,128 |
0 |
- |
|
| BIVV |
Bioverativ Inc. |
Chief Accounting Officer |
• • – |
2017-05-02 |
4 |
D |
$57.48 |
$5,691 |
D/D |
(99) |
2,946 |
0 |
- |
|
15 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
